Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a randomised study to examine whether high dose Sillymarin will be able to help
improve fat-induced liver damage in the liver. The study hypothesis is that high dose
Sillymarin will be able to reduce steato-hepatitis (fat-related liver inflammation) better
than placebo.